2μg (R: reducing condition, N:non-reducing condition).
CDCP1 His Tag Protein, Human
CDCP1 His Tag Protein, Human
Price:
Regular price
$245 USD
Regular price
Sale price
$245 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | CD318,TRASK,UNQ2486,Membrane glycoprotein gp140 |
| Accession | Q9H5V8-1 |
| Amino Acid Sequence | Phe30-Arg368 with His Tag at the C-Terminus |
| Expression System | HEK293 |
| Molecular Weight | 55-70kDa (Reducing) |
| Purity | ＞95% by SDS-PAGE&HPLC |
| Conjugation | Unconjugated |
| Tag | His Tag |
| Physical Appearance | Lyophilized powder |
| Storage Buffer | PBS, PH7.4, 5% trehalose |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
| Reference | 1.Chiu KL, Lin YS, Kuo TT, Lo CC, Huang YK, Chang HF, Chuang EY, Lin CC, Cheng WC, Liu YN, Lai LC, Sher YP. ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis. Oncotarget. 2017 Jul 18;8(29):47365-47378. |
Background
CDCP1 (CUB Domain Containing Protein 1, also known as SIMA135 or TRASK) is a single-pass transmembrane glycoprotein featuring three extracellular CUB domains and proteolytic cleavage sites; its intracellular segment activates Src family kinases (SFKs) via Y734 phosphorylation, thereby regulating cell adhesion, motility, and anoikis resistance. This protein can bind to integrin β1 to activate FAK/PI3K/Akt signaling and functions as a hypoxia-inducible factor-2α (HIF-2α) target gene under hypoxic regulation; in breast cancer and renal cell carcinoma, CDCP1 drives metastasis through promoting fatty acid oxidation and hypoxic adaptation, respectively. Clinical studies demonstrate that CDCP1 is highly expressed in melanoma, pancreatic cancer, prostate cancer, and other solid tumors, correlating with poor patient prognosis and castration-resistant prostate cancer progression, establishing it as a potential prognostic biomarker and therapeutic target, with anti-CDCP1 antibodies (such as 4A06) currently being investigated for theranostic targeted therapy applications, offering novel precision intervention strategies for metastatic malignancies.
Picture
Picture
SDS-PAGE
SEC-HPLC
The purity of CDCP1 His Tag Protein, Human is more than 95% determined by SEC-HPLC.
